Patents Assigned to TAP Pharmaceutical Products, Inc.
-
Publication number: 20090042887Abstract: The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis.Type: ApplicationFiled: January 17, 2008Publication date: February 12, 2009Applicant: TAP Pharmaceutical Products, Inc.Inventors: Christopher Lademacher, Patricia McDonald, Nancy Joseph Ridge, Rajneesh Taneja
-
Publication number: 20080292710Abstract: Liquid formulations of acid-labile drugs are provided. The formulations generally comprise micro-granules comprising an acid-labile drug coated with an enteric coating and a liquid vehicle having a pH less than 6.0. The components of the formulation can separately provided in the form of kits. The formulations and kits may be used to treat patients suffering from disorders for which the acid labile drugs are indicated.Type: ApplicationFiled: August 6, 2008Publication date: November 27, 2008Applicant: Tap Pharmaceutical Products, Inc.Inventor: Rajneesh Taneja
-
Publication number: 20080200516Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
-
Publication number: 20080200515Abstract: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
-
Publication number: 20080200517Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
-
Publication number: 20070244037Abstract: The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases.Type: ApplicationFiled: October 16, 2004Publication date: October 18, 2007Applicant: TAP PHARMACEUTICAL PRODUCTS INCInventors: Rudolf Richter, Reinhard Hen-Schler, Wolf-Georg Forssmann
-
Patent number: 6827208Abstract: The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medication components are contained in a plurality of compartments, which when a deforming force is applied are released into an outer containment pouch. The medication components can then be mixed together and dispensed from the outer pouch.Type: GrantFiled: December 18, 2002Date of Patent: December 7, 2004Assignee: TAP Pharmaceutical Products Inc.Inventors: Pramod Gupta, Rajneesh Taneja
-
Patent number: 6528521Abstract: A method for treating sexual dysfunction that is caused by anti-depressant medication in a patient in need of such treatment, comprising administering a therapeutically effective amount of apomorphine, or a pharmaceutically acceptable salt thereof to said patient, is disclosed. The method may be utilized for patients taking anti-depressants such as tricyclic anti-depressants, monamine oxidase inhibitors or serotonin selective reuptake inhibitors.Type: GrantFiled: November 14, 2001Date of Patent: March 4, 2003Assignee: Tap Pharmaceutical Products, Inc.Inventors: Dustin D. Ruff, Renee J. Perdok
-
Patent number: 6506765Abstract: Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apomorphine effectiveness for patients treated with apomorphine are disclosed. The apomorphine derivatives may be esters, ethers, amides, mixed anhydrides, hemiacetals, glucuronates, sulfates or phosphonates. A preferred apomorphine derivative is norapomorphine.Type: GrantFiled: March 29, 2001Date of Patent: January 14, 2003Assignee: TAP Pharmaceutical Products, Inc.Inventors: Pramod K. Gupta, Deborah Milkowski, Debra Sutkowski-Markmann